Clinical trial · Observational
Genomic BRCA and Extensive ovArian Cancer Testing
Cohort Study to Evaluate the Clinical Features of Patients With Epithelial Ovarian Cancer Depending on Tumoral Mutation of BRCA or Beyond BRCA Genomic Molecular Abnormalities
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Peritoneal Cancer | Malignant Peritoneal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Correlation between Progression Free Survival (PFS) and the detected tumor genetic abnormalities
- timeFrame
- From baseline until the date of progression or death, which ever occurs earlier, assessed up to 10 years
Secondary outcomes (6)
- measure
- Correlation between age and the detected tumor genetic abnormalities
- timeFrame
- Baseline
- measure
- Correlation between histology status and the detected tumor genetic abnormalities
- timeFrame
- Baseline
- measure
- Correlation between FIGO stage and the detected tumor genetic abnormalities
- timeFrame
- Baseline
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient older than 18 years. * Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014) * Patient in first line therapy * Available tumor sample fixed in formalin and included in paraffin (FFPE): * in pre-chemotherapy, insofar as possible * having a sufficient tumor surface, with a final cellularity of at least 20% * Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team * Patient consenting her data to be collected and submitted through an automated processing * Patient beneficiary from the French social security Exclusion Criteria: * Patient with a mucinous ovarian carcinoma * Patient pregnant or breastfeeding * Patient under legal protection (guardianship or court order) or unable to consent
References
Publications (0)
Data not yet available